8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF
1934
Date of Report (Date of earliest event reported): April 1, 2019
VistaGen Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
NEVADA
|
001-37761
|
20-5093315
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification Number)
|
343 Allerton Ave.
South San Francisco, California 94090
|
(Address of principal executive offices)
|
(650) 577-3600
(Registrant’s telephone number, including area
code)
Not Applicable
(Former name or former address, if changed since last
report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ Written communications
pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
☐ Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a
-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d -2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e -4(c))
Item 8.01 Other Events.
On April 1, 2019, VistaGen Therapeutics, Inc. (the
“Company”) announced additional results from
a positive pilot Phase 3 study of PH94B, a potential first-in-class
neuroactive nasal spray in development as an as-needed treatment
for social anxiety disorder. The new data was presented in a poster
session at the 2019 Anxiety and
Depression Association of America annual conference in
Chicago. A copy of the press release is attached to this Current
Report on Form 8-K as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
See
Exhibit Index.
Signatures
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
|
VistaGen
Therapeutics, Inc.
|
|
|
|
Date:
April 4, 2019
|
By:
|
/s/ Shawn K.
Singh
|
|
|
Shawn
K. Singh
Chief
Executive Officer
|
EXHIBIT INDEX
Exhibit No.
|
|
Description
|
|
|
|
|
|
Press
Release issued by VistaGen Therapeutics, Inc., dated April 1,
2019
|